Meta-analyses of FibroTest diagnostic value in chronic liver disease

BMC Gastroenterology

Volumn 7, Issue , 2007, Pages

  Poynard, Thierry ^a   Morra, Rachel ^a   Halfon, Philippe ^b   Castera, Laurent ^c   Ratziu, Vlad ^a   Imbert Bismut, Françoise ^a   Naveau, Sylvie ^d   Thabut, Dominique ^a   Lebrec, Didier ^e   Zoulim, Fabien ^f   Bourliere, Marc ^g   Cacoub, Patrice ^a   Messous, Djamila ^a   Munteanu, Mona ^h   de Ledinghen, Victor ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Laboratoire Alphabio   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

^e BEAUJON HOSPITAL   (France)

^f INSERM   (France)

^g HÔPITAL SAINT JOSEPH   (France)

^h Hopital Saint Joseph ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ALCOHOL LIVER DISEASE; ANALYTIC METHOD; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HEPATITIS B; HEPATITIS C; HUMAN; HYPOTHESIS; LIVER BIOPSY; LIVER FATTY DEGENERATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; META ANALYSIS; METHODOLOGY; NON INVASIVE PROCEDURE; PATHOGENESIS; RISK FACTOR; ROC CURVE; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SYSTEMATIC REVIEW; THEORY VALIDATION; BLOOD; CHRONIC DISEASE; LIVER DISEASE; LIVER FUNCTION TEST; PREDICTION AND FORECASTING;

BIOLOGICAL MARKERS; CHRONIC DISEASE; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; ROC CURVE;

EID: 38049125477     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-7-40     Document Type: Article

References (51)

1. Poynard T Imbert-Bismut F Munteanu M Messous D Myers RP Thabut D Ratziu V Mercadier A Benhamou Y Hainque B Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV-Fibrosure) and necrosis (ActiTest) in patients with chronic hepatitis C Comp Hepatol 2004, 3:8. 522750 15387887 10.1186/1476-5926-3-8
2. Poynard T Imbert-Bismut F Munteanu M Ratziu V FibroTest-FibroSURE:tOwards a universal biomarker of liver fibrosis? Expert Rev Mol Diag 2005, 5:15-21. 10.1586/14737159.5.1.15
3. Myers RP Tainturier MH Ratziu V Piton A Thibault V Imbert-Bismut F Messous D Charlotte F Di Martino V Benhamou Y Poynard T Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B J Hepatol 2003, 39:222-230. 10.1016/ S0168-8278(03)00171-5 12873819
4. Poynard T Zoulim F Ratziu V Degos F Imbert-Bismut F Deny P Landais P El Hasnaoui A Slama A Blin P Thibault V Parvaz P Munteanu M Trepo C Longitudinal assessment of histology surrogate markers (Fibrotest-Actitest) during lamivudine therapy in patients with chronic hepatitis B infection Am J Gast 2005, 100:1970-1980. 10.1111/ j.1572-0241.2005.41957.x
5. Naveau S Raynard B Ratziu V Abella A Imbert-Bismut F Messous D Beuzen F Capron F Thabut D Munteanu M Chaput JC Poynard T Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease Clin Gastroenterol Hepatol 2005, 3:167-174. 10.1016/ S1542-3565(04)00625-1 15704051
6. Callewaert N Van Vlierberghe H Van Hecke A Laroy W Delanghe J Contreras R Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics Nature Med 2004, 10:429-434. 10.1038/ nm1006 15152612
7. Cales P Oberti F Michalak S Hubert-Fouchard I Rousselet MC Konate A Gallois Y Ternisien C Chevailler A Lunel F A novel panel of blood markers to assess the degree of liver fibrosis Hepatology 2005, 42:1373-1381. 10.1002/hep.20935 16317693
8. Ratziu V Massard J Charlotte F Messous D Imbert-Bismut F Bonyhay L Tahiri M Munteanu M Thabut D Cadranel JF Le Bail B De Ledinghen V Poynard T the LIDO Study Group and the CYTOL Study Group Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease BMC Gastroenterology 2006, 6:6. 1386692 16503961 10.1186/1471-230X-6-6
9. Gebo KA Herlong HF Torbenson MS Jenckes MW Chander G Ghanem KG El-Kamary SS Sulkowski M Bass EB Role of liver biopsy in management of chronic hepatitis C: A systematic review Hepatology 2002, 36:S161-S172. 10.1002/ hep.1840360721 12407590
10. Sebastiani G Alberti A Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy World J Gastroenterol 2006, 12:3682-3694. 16773685
11. Poynard T Halfon P Castera L Charlotte F Bail BL Munteanu M Messous D Ratziu V Benhamou Y Bourliere M Ledinghen VD the Fibropaca group Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: Impact of biopsy length and fragmentation Aliment Pharmacol Ther 2007, 25:733-739. 17311607
12. Poynard T Halfon P Castera L Munteanu M Imbert-Bismut F Ratziu V Benhamou Y Bourliere M de Ledinghen V FibroPaca Group Standardization of ROC curve areas for diagnostic fvaluation of liver fibrosis markers based on prevalences of fibrosis Stages Clin Chem 2007, 53:1615-1622. 10.1373/clinchem.2007.085795 17634213
13. Bossuyt PM Reitsma JB Bruns DE Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative Clin Radiol 2003, 58:575-580. 10.1016/S0009-9260(03)00258-7 12887949
14. Easterbrook PJ Berlin JA Gopalan R Matthews DR Publication bias in clinical research Lancet 1991, 337:867-872. 10.1016/0140-6736(91)90201-Y 1672966
15. The French METAVIR Cooperative Study Group Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C Hepatology 1994, 20:15-20. 10.1002/hep.1840200104 8020885
16. Bedossa P Poynard T An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 1996, 24:289-293. 10.1002/hep.510240201 8690394
17. Bedossa P Dargère D Paradis V Sampling variability of liver fibrosis in chronic hepatitis C Hepatology 2003, 38:1449-1457. 14647056
18. DeLong ER DeLong DM Clarke-Pearson DL Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach Biometrics 1988, 44:837-45. 10.2307/2531595 3203132
19. Zhou X Obuchowski N McClish D Statistical Methods in Diagnostic Medicine John Wiley & Sons, New York; I 2002.
20. Hintze JL NCSS 2007 User Guide. Number Cruncher Statistical Systems software NCSS, Kaysville, Utah 2007.
21. Imbert-Bismut F Ratziu V Laurence Pieroni L Charlotte F Benhamou Y Poynard T MULTIVIRC Group Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study Lancet 2001, 357:1069-1075. 10.1016/S0140-6736(00)04258-6 11297957
22. Poynard T Imbert-Bismut F Ratziu V Chevret S Jardel C Moussalli J Messous D Degos F Biochemical markers of liver fibrosis in patients infected by Hepatitis C Virus: Longitudinal validation in a randomized trial J Viral Hepatitis 2002, 9:128-133. 10.1046/j.1365-2893.2002.00341.x
23. Poynard T McHutchison J Manns M Myers RP Albrecht J Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin Hepatology 2003, 38:481-492. 10.1053/jhep.2003.50319 12883493
24. Rossi E Adams L Prins A Bulsara M de Boer B Garas G MacQuillan G Speers D Jeffrey G Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients Clin Chem 2003, 49:450-454. 10.1373/49.3.450 12600957
25. Myers RP Benhamou Y Imbert-Bismut F Thibault V Bochet M Charlotte F Ratziu V Bricaire F Katlama C Poynard T Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients AIDS 2003, 17:1-5. 10.1097/ 00002030-200303280-00010 12478064
26. Castéra L Vergniol J Foucher J Brigitte Le Bail B Chanteloup E Haaser M Darriet M Couzigou P de Lédinghen V Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C Gastroenterology 2005, 128:343-350. 10.1053/j.gastro.2004.11.018 15685546
27. Colletta C Smirne C Fabris C Toniutto P Rapetti R Minisini R Pirisi M Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases Hepatology 2005, 42:838-845. 10.1002/hep.20814 16121354
28. Varaut A Fontaine H Serpaggi J Verkarre V Vallet-Pichard A Nalpas B Imbert Bismuth F Lebray P Pol S Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus Transplantation 2005, 80:1550-1555. 10.1097/ 01.tp.0000183399.85804.02 16371924
29. Halfon P Bourliere M Deydier R Portal I Renou R Bertrand J Trana A Rosenthal A Rotily M Sattonet A Independent prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C Am J Gastro 2006, 101:547-555. 10.1111/ j.1572-0241.2006.00411.x
30. Sebastiani G Vario A Guido M Noventa F Plebani M Pistis R Ferrari A Alberti A Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C J Hepatol 2006, 44:686-93. 10.1016/j.jhep.2006.01.007 16490278
31. Wilson LE Torbenson M Astemborski J Faruki H Spoler C Rai R Mehta S Kirk GD Nelson K Afdhal N Thomas DL Progression of liver fibrosis among injection drug users with chronic hepatitis C Hepatology 2006, 43:788-95. 10.1002/hep.21091 16557548
32. Sène D Limal N Djamila Messous D Ghillani-Dalbin P Charlotte F Halfon P Jean-Marie Thiollière JM Piette JC Imbert-Bismut F Halfon P Poynard T Cacoub P Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis Clin Biochem 2006, 39:715-721. 16765932
33. Sebastiani G Vario A Guido M Alberti A Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B World J Gastroenterol 2007, 13:525-731. 17278217
34. Poynard T Ngo Y Marcellin P Hadziyannis S Goodman Z Ratziu V Benhamou Y Brosgart CL Adefovir Dipivoxil 437 and 438 Study Groups Impact of adefovir dipivoxil on liver fibrosis and activity assessed with FibroTest-ActiTest in patients with chronic hepatitis B infection Abstract EASL, J Hepatol 2007, 46:S298.
35. Thabut D Naveau S Charlotte F Massard J Ratziu V Imbert-Bismut F Cazals-Hatem D Abella A Messous D Beuzen F Munteanu M Taieb J Moreau R Lebrec D Poynard T The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease J Hepatol 2006, 44:1175-85. 10.1016/ j.jhep.2006.02.010 16580087
36. Halfon P Bacq Y De Muret A Penaranda G Bourliere M Ouzan D Tran A Botta D Renou C Brechot MC Degott C Paradis V Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C J Hepatol 2007, 46:395-402. 10.1016/j.jhep.2006.09.020 17156890
37. Leroy V Hilleret MN Sturm N Trocme C Renversez JC Faure P Morel F Zarski JP Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C J Hepatol 2007, 46:775-782. 10.1016/j.jhep.2006.12.013 17321634
38. Coco B Oliveri F Maina AM Ciccorossi P Sacco R Colombatto P Bonino F Brunetto MR Transient elastography: A new surrogate marker of liver fibrosis influenced by major changes of transaminases J Vir Hep 2007, 14:360-369. 10.1111/j.1365-2893.2006.00811.x
39. Grigorescu M Rusu M Neculoiu D Radu C Aerban A Cathanao M Grigorescu MD The FibroTest Value in Discriminating between Insignificant and Significant Fibrosis in Chronic Hepatitis C Patients. The Romanian Experience Gastrointestin Liver Dis 2007, 16:31-37.
40. Poynard T Mathurin P Lai CL Guyader D Poupon R Tainturier MH Myers RP Muntenau M Ratziu V Manns M Vogel A Capron F Chedid A Bedossa P PANFIBROSIS Group A comparison of fibrosis progression in chronic liver diseases J Hepatol 2003, 38:257-265. 10.1016/S0168-8278(02)00413-0 12586290
41. Michalak S Rousselet MC Bedossa P Pilette C Chappard D Oberti F Gallois Y Cales P Respective roles of porto-septal fibrosis and centrilobular fibrosis in alcoholic liver disease J Pathol 2003, 201:55-62. 10.1002/ path.1412 12950017
42. Lieber CS CYP2E1: From ASH to NASH Hepatol Res 2004, 28:1-11. 10.1016/ j.hepres.2003.08.001 14734144
43. Munteanu M Poynard T Charlotte F Jacqueminet S Messous D Podevin P Serfaty L Bruckert E Grimaldi A Ratziu V Utility of a combination of non-invasive biomarkers (Fibromax) in assessing the efficacy of rosiglitazone in a one year randomized, double-blind trial in non alcoholic steatohepatitis Abstract EASL, J Hepatol 2007, 46:S298.
44. Bissell MD Assessing fibrosis without a liver biopsy: Are we there yet? Gastroenterology 2004, 127:1847-1849. 10.1053/j.gastro.2004.10.012 15578524
45. Rockey DC Bissell MD Noninvasive measures of liver fibrosis Hepatology 2006, 43:S113-S120. 10.1002/hep.21046 16447288
46. Poynard T Munteanu M Imbert-Bismut F Charlotte F Thabut D Le Calvez S Messous D Thibault V Benhamou Y Moussalli J Ratziu V Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C Clin Chem 2004, 50:1344-1355. 10.1373/ clinchem.2004.032227 15192028
47. Parkes J Indra Neil Guha IN Roderick P Rosenberg W Performance of serum marker panels for liver fibrosis in chronic hepatitis C J Hepatol 2006, 44:462-474. 10.1016/j.jhep.2005.10.019 16427156
48. Poynard T Ratziu V Benhamou Y Thabut D Moussalli J Biomarkers as a first-line estimate of injury in chronic liver diseases: Time for a moratorium on liver biopsy? Gastroenterology 2005, 128:1146-1148. 10.1053/j.gastro.2005.02.056 15825108
49. Castera L Denis J Babany G Roudot-Thoraval F Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: Time for new guidelines? J Hepatol 2007, 46:528-529. 10.1016/j.jhep.2006.12.002 17239479
50. http://www.biopredictive.com
51. La Haute Autorité de Santé (HAS) in France The HAS recommendations for the managemeMonant of the chronic hepatitis C using non-invasive biomarkers http://www.has-sante.fr/portail/ display.jsp?id=c_476486